Literature DB >> 35471571

Association of Perinatal and Childhood Ischemic Stroke With Attention-Deficit/Hyperactivity Disorder.

Jenny Bolk1,2,3, Eleni Simatou1,4, Jonas Söderling5, Lisa B Thorell6, Martina Persson1,2,3, Heléne Sundelin4,7.   

Abstract

Importance: Early detection of attention-deficit/hyperactivity disorder (ADHD) plays a crucial role in reducing negative effects on everyday life, including academic failure and poor social functioning. Children who survive ischemic strokes risk major disabilities, but their risk of ADHD has not been studied in nationwide cohorts. Objective: To assess the risk of ADHD in children after pediatric ischemic stroke. Design, Setting, and Participants: Participants in this Swedish nationwide cohort study included 1320 children diagnosed with ischemic stroke recorded in linked Swedish national registers from January 1, 1969, to December 31, 2016, without prior ADHD diagnosis. Ten matched controls were identified for each index case, and first-degree relatives were identified for index individuals and controls. Analyses were stratified by perinatal and childhood strokes and presence of comorbid adverse motor outcomes and/or epilepsy. End of follow-up was the date of ADHD diagnosis, death, or December 31, 2016, whichever occurred first. Data analyses were performed August 1 to 28, 2021. Exposures: Pediatric ischemic stroke. Main Outcomes and Measures: Attention-deficit/hyperactivity disorder identified using codes from the International Classification of Diseases, Ninth Revision, and International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, and/or prescribed ADHD medication recorded in the Medical Birth Register, National Patient Register, or Prescribed Drug Register after stroke. Cox proportional hazards regression was used to assess adjusted hazard ratios (aHRs) for ADHD after pediatric stroke, adjusting for parental age and ADHD in first-degree relatives.
Results: Of 1320 children with stroke included in the analysis (701 boys [53.1%]), 75 (45 boys [60.0%]) were diagnosed with ADHD after stroke compared with 376 (252 boys [67.0%]) among the controls (aHR, 2.00 [95% CI, 1.54-2.60]). The risk was increased after both perinatal (aHR, 2.75 [95% CI ,1.65-4.60]) and childhood (aHR, 1.82 [95% CI, 1.34-2.48]) strokes and were similar if children born preterm or small for gestational age were excluded. Compared with controls, risks of ADHD were higher among children with perinatal stroke and adverse motor outcomes and/or epilepsy (aHR, 6.17 [95% CI, 2.80-13.62]) than among those without these comorbidities (aHR, 1.65 [95% CI, 0.80-3.42]). However, findings were similar in childhood stroke for children with adverse motor outcomes and/or epilepsy (aHR, 1.80 [95% CI, 1.12-2.89]) and among those without these comorbidities (aHR, 1.92 [95% CI, 1.28-2.90]). Conclusions and Relevance: This cohort study of 1320 children with pediatric ischemic stroke suggests that there is an increased risk of ADHD, particularly in children with adverse motor outcomes and/or epilepsy, compared with controls. The risk increases after childhood strokes regardless of comorbidities.

Entities:  

Mesh:

Year:  2022        PMID: 35471571      PMCID: PMC9044107          DOI: 10.1001/jamanetworkopen.2022.8884

Source DB:  PubMed          Journal:  JAMA Netw Open        ISSN: 2574-3805


Introduction

Children who survive an ischemic stroke face higher risks of neurological disabilities, including epilepsy, and adverse motor outcomes such as hemiplegia and cerebral palsy.[1,2,3,4,5,6,7] Pediatric stroke may also increase the risk of attention-deficit/hyperactivity disorder (ADHD). The reported prevalence of ADHD after pediatric stroke has ranged from 13% to 50%.[8,9,10,11] However, it is unclear whether ADHD risk is increased in children with ischemic stroke who do not have these comorbidities. Symptoms of inattention and hyperactivity, as well as cognitive deficits in individuals with ADHD, often have a negative impact on academic achievements[12] and social functioning.[13] The prevalence of childhood ADHD in the general population is estimated to be approximately 3% to 5%.[13,14] Although the exact etiology of ADHD is often unclear, there is a strong hereditable component,[15] and associations have been found with low birth weight, prematurity,[16] male sex,[17] traumatic brain injuries, and brain tumors.[18,19] It has been reported that 19% to 35% of children with cerebral palsy also have ADHD,[20] which is approximately 6 times higher than in the general population. Children with epilepsy also have a 2.5 to 5.5 times higher risk of ADHD.[21] Numerous studies have reported that cerebral palsy and epilepsy are common comorbidities after pediatric stroke,[1,2,3,4,5,6,7,22] so we would also expect to see an increased risk of ADHD. However, it is unclear whether the risk of ADHD is increased in children with ischemic stroke who do not have these comorbidities. Previous studies assessing ADHD after pediatric stroke[8,9,10,11] have had limited sample sizes and used varying definitions of ADHD. They have also been hospital based and/or did not include general population controls, which restricted the generalizability of their results. The main aim of our study was to address these limitations by using data from nationwide registers to evaluate the risk of ADHD after pediatric ischemic stroke in a large cohort of children. We included family history of ADHD, prematurity, small for gestational age (SGA), comorbid adverse motor outcomes, and epilepsy in our analysis. We hypothesized that children who had pediatric stroke face a higher risk of ADHD even if not born preterm or SGA or not having comorbid adverse motor outcomes and/or epilepsy. Our secondary aim was to explore whether ADHD and ischemic stroke have a shared heredity. Because diverse conditions affecting the brain have been reported to be genetically related,[23,24,25] we hypothesized that first-degree relatives of patients who had pediatric stroke would have an increased risk of ADHD. We explored this hypothesis by assessing the risk of ADHD in first-degree relatives of patients with pediatric stroke without ADHD.

Methods

Study Design and Study Population

This Swedish nationwide cohort study included children who were younger than 18 years with ischemic stroke between January 1, 1969, and December 31, 2016, and were alive 1 week after their stroke. They were identified using the National Patient Register[26,27] and the Medical Birth Register.[28] Individuals with ADHD before their stroke were excluded. The Total Population Register[26] was used to identify 10 controls for each patient with stroke who were matched for sex, year of birth, and county of residence at the time of diagnosis. Parents, siblings, and offspring of patients and controls were identified from the Multigeneration Register, which is part of the Total Population Register. This cohort is part of PedStroke, a Swedish national study on pediatric stroke. Previous publications report mortality,[29] risk of epilepsy,[22] and adverse motor outcomes[30] in the cohort. The study was approved by the regional ethics committee in Linköping. The authors had access to pseudonymized and encrypted data from Statistics Sweden only, therefore the ethics committee did not require individual informed consent.[31] This report followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) and the Reporting of Studies Conducted Using Observational Routinely Collected Health Data (RECORD) reporting guidelines.

Assessment Methods

Exposure consisted of ischemic stroke at younger than 18 years, defined by codes from the International Classification of Diseases, Eighth Revision (ICD-8), International Classification of Diseases, Ninth Revision (ICD-9), and International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) (eTable 1 in the Supplement). Outcome consisted of a register entry of ADHD after the stroke diagnosis, defined by the relevant ICD-9 or ICD-10 code and/or prescription of ADHD medication documented in the Prescribed Drug Register[32] (eTable 1 in the Supplement).

Variables Used for Adjusted and Stratified Analyses

Perinatal stroke was defined as a diagnosis of an ischemic stroke 28 days after birth or earlier; childhood strokes were diagnosed after 28 days but before 18 years of age. Preterm birth was defined as birth before 37 plus 0 gestational weeks, and SGA was defined as birth weight of less than −2 SD for the mean birth weight for gestational age and sex according to Swedish reference data.[33] Adverse motor outcomes consisted of a diagnosis of cerebral palsy, hemiparesis, tetraparesis, paraplegia, or any other paresis. These, together with epilepsy, were based on the ICD-8, ICD-9, and ICD-10 codes in the National Patient Register (eTable 1 in the Supplement).

Data Sources

The data from the Swedish national registers were linked using the unique personal registration number assigned to all residents at birth or immigration.[34] The National Patient Register[27] is a validated register[26] that provides diagnostic information on Swedish residents since 1964, including all inpatient hospital care since 1987 and outpatient care since 2001. The Medical Birth Register[28] prospectively collects information on antenatal and perinatal factors and neonatal diagnoses and covers more than 98% of Swedish births. The Prescribed Drug Register[32] provides information on all prescribed drugs dispensed by Swedish pharmacies since 2005. The Multi-generation Register[35,36] and the Total Population Register have almost complete coverage in individuals born from 1961 onward. Owing to the high coverage of the registers, all individuals in Sweden except very few cases are included when linking data from these registers. The validity of the diagnoses of pediatric ischemic stroke in the National Patient Register and Medical Birth Register has been evaluated to be high. Review of medical records of parts of our cohort resulted in an overall positive predicted value of 89% for pediatric ischemic stroke, 96% for perinatal ischemic stroke, and 84% for childhood ischemic stroke.[37] Diagnoses of ADHD in the National Patient Register and Prescribed Drug Register have also shown high validity.[38] The registers were accessed on December 31, 2016.

Statistical Analysis

Follow-up started at the date of stroke diagnosis and the corresponding date for the controls and ended at the first ADHD diagnosis, death, or December 31, 2016, whichever came first. The follow-up for first-degree relatives started at birth and ended as described above. When stratifying by comorbidity, follow-up started at the date of the first diagnosis of adverse motor outcomes and/or epilepsy. Cox proportional hazards regression was used to calculate hazard ratios (HRs) and assess the risk of ADHD after stroke. Each index individual was compared with his or her matched controls using an internal stratifying model. Analyses were adjusted for parental age at the birth of the child and for any ADHD diagnosis of parents and siblings. Unadjusted results can be found in eTables 2 and 3 in the Supplement. Separate analyses were performed for perinatal strokes and childhood strokes because these conditions have somewhat separate clinical symptoms and treatments. Sensitivity analyses were performed separately for children not born preterm or SGA, for sex, and for children with and without adverse motor outcomes and/or epilepsy because all these conditions have been reported to increase the risk of ADHD.[15,16,17] We performed sensitivity analyses for individuals without adverse motor outcomes or epilepsy by censoring at the time of the first diagnosis of adverse motor outcomes or epilepsy after stroke. We also evaluated the risk of ADHD in parents, siblings, and offspring of children with stroke and controls. The data analyses were performed from August 1 to 28, 2021, using SAS statistical software, version 9.4 (SAS Institute Inc), and Stata, version 16.0 (StataCorp LLC). A 95% CI that excluded 1.00 defined statistical significance.

Results

Study Population and Baseline Characteristics

After excluding 7 children with ADHD before their stroke, 1320 individuals who were younger than 18 years and had pediatric stroke between 1969 and 2016 (343 with perinatal stroke and 977 with childhood stroke) (Figure) were included in the analysis (701 boys [53.1%] and 619 girls [46.9%]). Baseline characteristics are presented in Table 1. Of the 1320 children, 75 (45 boys [60.0%] and 30 girls [40.0%]) were diagnosed with ADHD after stroke compared with 376 (252 boys [67.0%] and 124 girls [33.0%]) among the controls (adjusted HR [aHR], 2.00 [95% CI, 1.54-2.60]) (Table 2).
Figure.

Flowchart of Study Population

ADHD indicates attention-deficit/hyperactivity disorder.

Table 1.

Baseline Characteristics for Individuals Who Had a Pediatric Ischemic Stroke and Matched Controls

CharacteristicCohort groupa
Children with pediatric ischemic stroke (n = 1320)Matched controls (n = 13 141)
Demographic variables
Sex
Boys701 (53.1)6970 (53.0)
Girls619 (46.9)6171 (46.9)
Age at first stroke diagnosis
Perinatal stroke (≤28 d)343 (26.0)3429 (26.1)
Childhood stroke (>28 d)977 (74.0)9712 (73.9)
Year of first stroke diagnosis
1969-1986136 (10.3)1360 (10.3)
1987-1996313 (23.7)3129 (23.8)
1997-2005253 (19.2)2527 (19.2)
2006-2016618 (46.8)6125 (46.6)
Perinatal variables
Small for gestational age78 (5.9)347 (2.6)
Missing birth weight178 (13.5)1612 (12.3)
Born preterm (<37 plus 0 wk)123 (9.3)671 (5.1)
Missing gestational age165 (12.5)1592 (12.1)
Comorbidity
Adverse motor outcomeb424 (32.1)43 (0.3)
Epilepsyc303 (22.9)120 (0.9)
Maternal age at birth of child
Median (IQR), y29.2 (25.5-33.1)29.2 (25.4-33.1)
Missing data7 (0.5)108 (0.8)
Paternal age at birth of child
Median (IQR), y31.9 (27.8-36.0)31.7 (27.8-36.0)
Missing data29 (2.2)301 (2.3)

Indicates after exclusion criteria were applied: individuals who died within the first week after a pediatric ischemic stroke or had a diagnosis of attention-deficit/hyperactivity disorder within 1 week after their stroke, along with the data from their matched controls. Unless otherwise indicated, data are expressed as number (%) of patients or controls.

Adverse motor outcome was defined as International Classification of Diseases, Eighth Revision (ICD-8), codes 343 and 344 (except 344.B, 344.C, and 344.G), International Classification of Diseases, Ninth Revision (ICD-9), codes 343, 342, and 344 (except 344.01 and 344.03), and International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10), codes (G80, G81, G82, and G83, except G83.0 and G83.4-6).

Epilepsy was defined as ICD-8 code 345 (except 345.2), ICD-9 code 345 (except 345Q), and ICD-10 code G40.

Table 2.

Risk of ADHD After Pediatric Ischemic Stroke

Characteristic Cohort group, No. (%)Diagnosis of ADHD, No. (%)Incidence rate per 1000 person-years, HR (95% CI)Adjusted HR (95% CI)b
Children with pediatric strokeMatched controlsChildren with pediatric strokeMatched controlsChildren with pediatric strokeMatched controls
Overall1320 (100)13 141 (100)75 (5.7)376 (2.9)4.2 (3.3-5.2)2.0 (1.8-2.2)2.00 (1.54-2.60)
Sex
Boys701 (53.1)6970 (53.0)45 (6.4)252 (3.6)4.7 (3.3-6.1)2.4 (2.1-2.7)1.78 (1.27-2.49)
Girls619 (46.9)6171 (46.9)30 (4.8)124 (2.0)3.7 (2.4-5.0)1.4 (1.2-1.7)2.45 (1.61-3.72)
Age at first stroke diagnosis
Perinatal343 (26.0)3429 (26.1)21 (6.1)76 (2.2)5.6 (3.2-8.0)1.9 (1.5-2.3)2.75 (1.65-4.60)
Childhood977 (74.0)9712 (73.9)54 (5.5)300 (3.1)3.9 (2.8-4.9)2.0 (1.8-2.2)1.82 (1.34-2.48)
Year of first stroke diagnosis
1986 or earlier136 (10.3)1360 (10.3)1 (0.7)25 (1.8)0.2 (0.0-0.7)0.5 (0.3-0.7)0.38 (0.05-2.92)
1987-1996313 (23.7)3129 (23.8)10 (3.2)106 (3.4)1.4 (0.5-2.3)1.4 (1.1-1.7)1.04 (0.53-2.02)
1997-2005253 (19.2)2527 (19.2)30 (11.9)138 (5.5)9.1 (5.8-12.4)3.8 (3.2-4.4)2.12 (1.39-3.23)
2006-2016618 (46.8)6125 (46.6)34 (5.5)107 (1.7)11.1 (7.4-14.8)3.4 (2.7-4.0)3.19 (2.10-4.86)

Abbreviations: ADHD, attention-deficit/hyperactivity disorder; HR, hazard ratio.

Attention-deficit/hyperactivity disorder was defined according to International Classification of Diseases, Ninth Revision, code 314 and International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, code F90 and/or if the patient was in receipt of ADHD medication in the Prescribed Drug Register according to the Anatomical Therapeutic Chemical classification system codes N06BA01 to N06BA06, N06BA08 to N06BA12, and/or C02AC02 (guanfacine). Of the 75 index children with ADHD, 57 had been prescribed ADHD medication; of the 376 controls with ADHD, 324 had been prescribed ADHD medication. Individuals who died within the first week after a pediatric ischemic stroke or had a diagnosis of ADHD within 1 week after their stroke were excluded along with the data from their matched controls.

Conditioned on matching set (age, sex, year of birth, and county of residence at the time of stroke) and adjusted for maternal and paternal age at the birth of the child and any ADHD in parents or siblings.

Flowchart of Study Population

ADHD indicates attention-deficit/hyperactivity disorder. Indicates after exclusion criteria were applied: individuals who died within the first week after a pediatric ischemic stroke or had a diagnosis of attention-deficit/hyperactivity disorder within 1 week after their stroke, along with the data from their matched controls. Unless otherwise indicated, data are expressed as number (%) of patients or controls. Adverse motor outcome was defined as International Classification of Diseases, Eighth Revision (ICD-8), codes 343 and 344 (except 344.B, 344.C, and 344.G), International Classification of Diseases, Ninth Revision (ICD-9), codes 343, 342, and 344 (except 344.01 and 344.03), and International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10), codes (G80, G81, G82, and G83, except G83.0 and G83.4-6). Epilepsy was defined as ICD-8 code 345 (except 345.2), ICD-9 code 345 (except 345Q), and ICD-10 code G40. Abbreviations: ADHD, attention-deficit/hyperactivity disorder; HR, hazard ratio. Attention-deficit/hyperactivity disorder was defined according to International Classification of Diseases, Ninth Revision, code 314 and International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, code F90 and/or if the patient was in receipt of ADHD medication in the Prescribed Drug Register according to the Anatomical Therapeutic Chemical classification system codes N06BA01 to N06BA06, N06BA08 to N06BA12, and/or C02AC02 (guanfacine). Of the 75 index children with ADHD, 57 had been prescribed ADHD medication; of the 376 controls with ADHD, 324 had been prescribed ADHD medication. Individuals who died within the first week after a pediatric ischemic stroke or had a diagnosis of ADHD within 1 week after their stroke were excluded along with the data from their matched controls. Conditioned on matching set (age, sex, year of birth, and county of residence at the time of stroke) and adjusted for maternal and paternal age at the birth of the child and any ADHD in parents or siblings.

ADHD Risk After Pediatric Ischemic Stroke

The 1320 index individuals with pediatric stroke were twice as likely to have ADHD compared with controls when adjusting for parental age and a family history of ADHD (aHR, 2.00 [95% CI, 1.54-2.60]). The risk was similar between boys (aHR, 1.78 [95% CI, 1.27-2.49]) and girls (aHR, 2.45 [95% CI, 1.61-3.72]) (Table 2). This increased risk remained after excluding individuals born SGA and/or preterm (aHR, 2.19 [95% CI, 1.62-2.97]) (Table 3).
Table 3.

Risk of ADHD After Pediatric Ischemic Stroke When Considering Perinatal Variables and Stroke Comorbidities

GroupCohort group, No. (%)Diagnosis of ADHD, No. (%)Incidence rate per 1000 person-years, HR (95% CI)Adjusted HR (95% CI)b
Children with pediatric stroke (n = 1320)Matched controls (n = 13 141)Children with pediatric strokeMatched controlsChildren with pediatric strokeMatched controls
After excluding children who were born preterm (<37 plus 0 wk) and/or small for gestational age
Overall967 (73.3)8320 (63.3)58 (6.0)244 (2.9)4.9 (3.7-6.2)2.2 (2.0-2.5)2.19 (1.62-2.97)
Perinatal stroke283 (21.4)2557 (19.5)17 (6.0)53 (2.1)5.7 (3.0-8.4)1.9 (1.4-2.4)3.16 (1.78-5.61)
Childhood stroke684 (51.8)5763 (43.9)41 (6.0)191 (3.3)4.7 (3.2-6.1)2.4 (2.0-2.7)1.94 (1.35-2.77)
Stratification according to comorbidity, with follow-up from diagnosis of adverse motor outcomes or epilepsy
Children with adverse motor outcomes
Overall422 (32.0)4183 (31.8)28 (6.6)120 (2.9)6.4 (4.0-8.7)2.4 (2.0-2.8)2.10 (1.35-3.27)
Perinatal stroke100 (7.6)991 (7.5)8 (8.0)15 (1.5)9.8 (3.0-16.5)1.7 (0.9-2.6)5.73 (2.34-14.03)
Childhood stroke322 (24.4)3192 (24.3)20 (6.2)105 (3.3)5.6 (3.1-8.1)2.5 (2.1-3.0)1.60 (0.95-2.70)
Children with epilepsy
Overall293 (22.2)2906 (22.1)21 (7.2)77 (2.6)8.1 (4.6-11.5)2.6 (2.0-3.1)3.54 (2.13-5.90)
Perinatal stroke80 (6.1)796 (6.1)8 (10.0)15 (1.9)12.4 (3.8-21.1)2.2 (1.1-3.3)5.69 (2.28-14.20)
Childhood stroke213 (16.1)2110 (16.1)13 (6.1)62 (2.9)6.6 (3.0-10.3)2.7 (2.0-3.3)2.93 (1.56-5.48)
Children with adverse motor outcomes and/or epilepsy
Overall531 (40.2)5255 (40.0)35 (6.6)145 (2.7)6.3 (4.2-8.4)2.3 (1.9-2.7)2.37 (1.59-3.53)
Perinatal stroke129 (9.8)1277 (9.7)11 (8.5)20 (1.6)10.0 (4.1-15.9)1.7 (1.0-2.5)6.17 (2.80-13.62)
Childhood stroke402 (30.5)3978 (30.3)24 (6.0)125 (3.1)5.4 (3.2-7.6)2.4 (2.0-2.9)1.80 (1.12-2.89)
Censoring at time of first diagnosis of adverse motor outcomes and/or epilepsy
Children with adverse motor outcomes were censored
Overall1320 (100)13 141 (100)47 (3.6)374 (2.8)3.5 (2.5-4.5)2.0 (1.8-2.1)1.95 (1.40-2.71)
Perinatal stroke343 (26.0)3429 (26.1)13 (3.8)76 (2.2)4.4 (2.0-6.9)1.9 (1.5-2.3)1.99 (1.04-3.79)
Childhood stroke977 (74.0)9712 (73.9)34 (3.5)298 (3.1)3.3 (2.2-4.3)2.0 (1.7-2.2)1.99 (1.35-2.93)
Children with epilepsy were censored
Overall1320 (100)13 141 (100)54 (4.1)366 (2.8)3.6 (2.6-4.5)1.9 (1.7-2.1)1.69 (1.24-2.31)
Perinatal stroke343 (26.0)3429 (26.1)13 (3.8)74 (2.2)4.2 (1.9-6.5)1.8 (1.4-2.3)2.05 (1.08-3.92)
Childhood stroke977 (74.0)9712 (73.9)41 (4.2)292 (3.0)3.4 (2.4-4.4)1.9 (1.7-2.2)1.62 (1.13-2.31)
Children with adverse motor outcomes and/or epilepsy were censored
Overall1320 (100)13 141 (100)40 (3.0)364 (2.8)3.3 (2.3-4.3)1.9 (1.7-2.1)1.81 (1.26-2.59)
Perinatal stroke343 (26.0)3429 (26.1)10 (2.9)74 (2.2)3.8 (1.4-6.1)1.8 (1.4-2.3)1.65 (0.80-3.42)
Childhood stroke977 (74.0)9712 (73.9)30 (3.1)290 (3.0)3.1 (2.0-4.3)1.9 (1.7-2.1)1.92 (1.28-2.90)

Abbreviations: ADHD, attention-deficit/hyperactivity disorder; HR, hazard ratio.

Attention-deficit/hyperactivity disorder was defined according to International Classification of Diseases, Ninth Revision, code 314 and International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, code F90 and/or if the patient was in receipt of ADHD medication in the Prescribed Drug Register according to the Anatomical Therapeutic Chemical classification system codes N06BA01 to N06BA06, N06BA08 to N06BA12, and/or C02AC02 (guanfacine). Individuals who died within the first week after a pediatric ischemic stroke or had a diagnosis of ADHD within 1 week after their stroke were excluded along with the data from the matched controls.

Conditioned on matching set (age, sex, year of birth, and county of residence at the time of stroke) and adjusted for maternal and paternal age at the birth of the child and any ADHD in parents or siblings.

Abbreviations: ADHD, attention-deficit/hyperactivity disorder; HR, hazard ratio. Attention-deficit/hyperactivity disorder was defined according to International Classification of Diseases, Ninth Revision, code 314 and International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, code F90 and/or if the patient was in receipt of ADHD medication in the Prescribed Drug Register according to the Anatomical Therapeutic Chemical classification system codes N06BA01 to N06BA06, N06BA08 to N06BA12, and/or C02AC02 (guanfacine). Individuals who died within the first week after a pediatric ischemic stroke or had a diagnosis of ADHD within 1 week after their stroke were excluded along with the data from the matched controls. Conditioned on matching set (age, sex, year of birth, and county of residence at the time of stroke) and adjusted for maternal and paternal age at the birth of the child and any ADHD in parents or siblings. Compared with controls, the risk of developing ADHD was similar for the 422 children with adverse motor outcomes after stroke (aHR, 2.10 [95% CI, 1.35-3.27]) and among those without adverse motor outcomes (aHR, 1.95 [95% CI, 1.40-2.71]). The 293 children who had epilepsy after stroke had a slightly higher risk of ADHD compared with controls (aHR, 3.54 [95% CI, 2.13-5.90]) than among those who did not develop epilepsy (aHR, 1.69 [95% CI, 1.24-2.31]) (Table 3).

Risk of ADHD After Perinatal Stroke

The 343 children with perinatal stroke also had an increased risk of ADHD (aHR, 2.75 [95% CI, 1.65-4.60]) (Table 2), which remained similar when excluding individuals born preterm or SGA (aHR, 3.16 [95% CI, 1.78-5.61]) (Table 3). The ADHD risk was elevated among all children with perinatal stroke and adverse motor outcomes and/or epilepsy (aHR, 6.17 [95% CI, 2.80-13.62]). The ADHD risk was also elevated compared with controls in the 100 patients with perinatal stroke who developed adverse motor outcome (aHR, 5.73 [95% CI, 2.34-14.03]) than among those without adverse motor outcomes (aHR, 1.99 [95% CI, 1.04-3.79]). In addition, the 80 patients with perinatal stroke and epilepsy had a higher risk compared with controls (aHR, 5.69 [95% CI, 2.28-14.20]) than among those without epilepsy (aHR, 2.05 [95% CI, 1.08-3.92]) (Table 3). When censoring the 129 children with adverse motor outcomes and/or epilepsy at time of the first diagnosis of adverse motor outcomes or epilepsy, the risk of ADHD was no longer increased in children with perinatal stroke (aHR, 1.65 [95% CI, 0.80-3.42]) (Table 3).

Risk of ADHD After Childhood Stroke

The risk of ADHD after childhood stroke was increased (aHR, 1.82 [95% CI, 1.34-2.48]) (Table 2), and it remained similar when excluding children born preterm or SGA (aHR, 1.94 [95% CI, 1.35-2.77]) (Table 3). The risk for ADHD was elevated among all children with childhood stroke who had adverse motor outcomes and/or epilepsy (aHR, 1.80 [95% CI, 1.12-2.89]). The risk of ADHD compared with controls was similar for the 322 children with adverse motor outcomes (aHR, 1.60 [95% CI, 0.95-2.70]) than among those without adverse motor outcomes (aHR, 1.99 [95% CI, 1.35-2.93]). The risk of ADHD compared with controls in the 213 children with childhood stroke who had epilepsy was not significantly higher (aHR, 2.93 [95% CI, 1.56-5.48]) than among children without epilepsy (aHR, 1.62 [95% CI, 1.13-2.31]). After censoring the 402 individuals with comorbid adverse motor outcomes and/or epilepsy, the risk of ADHD was still increased (aHR, 1.92 [95% CI, 1.28-2.90]) (Table 3).

Risk of ADHD in Relatives of Patients With Stroke

The siblings of patients with stroke had a higher risk of ADHD than the siblings of controls (aHR, 1.38 [95% CI, 1.09-1.74]), and the same result was seen for both perinatal and childhood stroke (Table 4). When only including patients with pediatric stroke and without ADHD, the risk of ADHD in siblings was still elevated (aHR, 1.47 [95% CI, 1.14-1.90]).
Table 4.

Risk of ADHD in Parents, Siblings, and Offspring of Individuals With Pediatric Ischemic Stroke

Included individualsADHD cases in relatives, No. (%)HR (95% CI)Adjusted HR (95% CI)a
Children with pediatric ischemic strokeMatched controls
With or without ADHD
Overall160 (2.8)1026 (2.0)1.45 (1.23-1.72)1.46 (1.23-1.73)
Siblings100 (4.4)594 (3.5)1.37 (1.09-1.72)1.38 (1.09-1.74)
Parents46 (1.5)342 (1.1)1.34 (0.98-1.84)1.30 (0.92-1.83)
Offspring14 (4.6)90 (4.1)1.26 (0.67-2.37)1.32 (0.70-2.50)
Perinatal stroke (aged ≤28 d)37 (3.1)228 (2.1)1.54 (1.08-2.19)1.54 (1.07-2.19)
Stroke in childhood (aged >28 d)123 (2.7)798 (2.0)1.43 (1.18-1.73)1.43 (1.18-1.74)
Without ADHD
Overall137 (2.5)851 (1.7)1.54 (1.28-1.85)1.53 (1.27-1.84)
Siblings85 (4.0)500 (3.0)1.48 (1.15-1.90)1.47 (1.14-1.90)
Parents38 (1.3)269 (0.9)1.50 (1.06-2.13)1.42 (0.96-2.08)
Offspring14 (4.7)82 (3.8)1.40 (0.74-2.65)1.46 (0.77-2.78)

Abbreviations: ADHD, attention-deficit/hyperactivity disorder; HR, hazard ratio.

Adjusted for maternal and paternal age at the birth of the child.

Abbreviations: ADHD, attention-deficit/hyperactivity disorder; HR, hazard ratio. Adjusted for maternal and paternal age at the birth of the child.

Discussion

This nationwide cohort study of 1320 patients with pediatric stroke identified a 2-fold increased risk of ADHD after pediatric ischemic stroke. That risk remained increased after known risk factors for ADHD were considered, such as a family history of ADHD,[15] parental age,[39] prematurity, or SGA.[16] The increased risk was seen after both perinatal and childhood stroke, which is in line with the study by Williams et al.[10] Other studies[9,11] did not distinguish between perinatal and childhood strokes. Epilepsy and adverse motor outcomes have been associated with ADHD in the general population[21,40] and are common sequelae after pediatric stroke.[41,42] Therefore, we also ran sensitivity analyses that censored individuals with these comorbidities. Previous studies have also reported increased risks of ADHD diagnosis or ADHD symptom level after pediatric strokes.[9,10,11,43] However, most of these studies included small cohorts.[9,11,43] The exception was the study by Williams et al,[10] which included 275 patients with pediatric stroke. To our knowledge, this is also the only study except ours that accounted for family history of ADHD. To our knowledge, our study is the largest to date to report an increased risk of a clinical diagnosis of ADHD after pediatric stroke. The risk of ADHD was increased after perinatal stroke and increased 6 times if the child also had adverse motor outcomes. The expected adverse motor outcome after perinatal stroke is cerebral palsy. Attention-deficit/hyperactivity disorder is more common in individuals with cerebral palsy than in the general population,[20] and a Swedish population-based study[44] reported that half of the 200 children with cerebral palsy had positive results for ADHD. As expected, children diagnosed with comorbid epilepsy after perinatal stroke had a higher risk of ADHD compared with controls than those with perinatal stroke without epilepsy. This result echoed the findings of Williams et al[10] and Auvin et al.[21] Clinicians are already advised to screen for ADHD when children have epilepsy because this outcome is a well-known comorbid condition.[21] Genetic and environmental factors can contribute to the comorbidity of ADHD in epilepsy, as well as an imbalance between excitation and inhibition in the brain.[45] This imbalance could also contribute to the development of ADHD.[46] The risk of ADHD was also increased after childhood stroke, and the presence of adverse motor outcomes was not associated with the risk. Adverse motor outcomes after childhood stroke most commonly consist of hemiplegia and, for some of the younger children, cerebral palsy, in addition to less severe palsies and paresis that are often caused by a smaller insult to the brain. Epilepsy seems to be a risk factor for ADHD after both childhood and perinatal strokes. However, compared with controls, the risk of ADHD was also increased after childhood stroke for those without adverse motor outcomes or epilepsy. It has been reported that the risk of ADHD is increased after other brain insults during childhood, such as severe traumatic brain injuries.[18] In these cases, a decrease in the organization of white matter seems to play a crucial role in the development of ADHD,[47] and this decrease could also be important in other disorders. Whether this outcome is the case after pediatric stroke needs to be elucidated.

Risk of ADHD in First-Degree Relatives of Patients With Stroke

We found an increased risk of ADHD in the siblings of patients with pediatric stroke with and without ADHD. The rationale behind evaluating ADHD in relatives of these patients is that previous research[23] has demonstrated a high degree of genetic correlation between different psychiatric disorders. Thus, our results support the hypothesis that there is a genetic disposition that increases the risk of both ADHD and stroke.

Strengths and Limitations

To our knowledge, this is the largest study of risk of ADHD in patients with pediatric stroke to date, and our results confirm findings of smaller, hospital-based studies.[9,10,11] Pediatric stroke is a relatively rare event, and this factor resulted in low power in most of the previous studies. Another major strength of the present study is its nationwide design. As recommended for follow-up studies,[48] we matched controls and compared risks of ADHD between patients with stroke and controls. All data were collected prospectively. We adjusted for important confounders, such as ADHD in first-degree relatives, parental age, prematurity, and SGA. A diagnosis of ADHD was identified based on clinical ICD-9 and ICD-10 codes in contrast to previous studies using diagnoses based on questionnaires or research tests,[11,43] which may overestimate the prevalence of ADHD.[49] Stratified analyses of the risks of perinatal or childhood strokes and neurological comorbidities were performed. Data were retrieved from registers with high validity. The stroke diagnosis in our cohort has been validated. This study has some limitations. There is a possibility of detection bias by misclassification or underreporting, such as underreporting of stroke before the advent of modern imaging, and for surveillance bias if patients with stroke were more carefully observed. Some individuals might have had ADHD before the stroke, although the ADHD diagnosis was registered after the stroke. Fewer controls had ADHD (2.9%) than previously reported in Swedish national registers (4.3%),[50] possibly because the follow-up time was limited to the date of the stroke diagnosis in the matched index case and that a diagnosis code for ADHD is only available after ICD-9 was implemented in 1987. The number of individuals in the exposed group was relatively small for some analyses, with wide 95% CIs for some aHRs. If possible, our results should therefore be confirmed in other large cohorts of patients with pediatric stroke. Owing to the limited number of individuals in some subgroups, we were also only able to report results compared with controls instead of making direct comparisons between children with and without comorbidities. We could not distinguish between different types of ischemic stroke, but a previous validation study[37] showed that 90% were arterial ischemic strokes. The proportion of perinatal strokes in our cohort was lower than expected. Some neonatal units may have used unspecific ICD codes (eg, cerebral ischemia) for perinatal stroke cases. Our study population was probably heterogenous in terms of the localization and size of the strokes. Outpatient diagnoses of ADHD have only been available since 2001. However, we estimate risks compared with controls, and the risks are probably not as influenced by this factor as the prevalence rates. We did not evaluate other mental health outcomes, socioeconomic status, parental health, or other child health variables that could have influenced our findings. In addition, we cannot rule out unmeasured and residual confounding variables that may have influenced the result.

Conclusions

The findings of this nationwide cohort study suggest that pediatric ischemic stroke was associated with a risk of ADHD irrespective of whether there was a family history of ADHD. This risk was even higher if there were adverse motor outcomes and/or epilepsy after perinatal stroke. Furthermore, the risk was increased in patients with childhood stroke who did not have these comorbidities. Ongoing surveillance for signs of ADHD should form an important part of follow-up programs after pediatric strokes, especially if individuals have comorbid adverse motor outcomes or epilepsy.
  47 in total

Review 1.  Perinatal arterial ischemic stroke: presentation, risk factors, evaluation, and outcome.

Authors:  Laura L Lehman; Michael J Rivkin
Journal:  Pediatr Neurol       Date:  2014-08-14       Impact factor: 3.372

2.  Paediatric ischaemic stroke is a valid diagnosis in the Swedish National Patient Register.

Authors:  Anna Walås; Katarina Svensson; Maria Gyris; Peter Bang; Heléne E K Sundelin
Journal:  Acta Paediatr       Date:  2021-02-14       Impact factor: 2.299

3.  Systematic review of the screening, diagnosis, and management of ADHD in children with epilepsy. Consensus paper of the Task Force on Comorbidities of the ILAE Pediatric Commission.

Authors:  Stéphane Auvin; Elaine Wirrell; Kirsten A Donald; Madison Berl; Hans Hartmann; Kette D Valente; Patrick Van Bogaert; J Helen Cross; Makiko Osawa; Hideaki Kanemura; Masao Aihara; Marilisa M Guerreiro; Pauline Samia; Kollencheri Puthenveettil Vinayan; Mary Lou Smith; Lionel Carmant; Michael Kerr; Bruce Hermann; David Dunn; Jo M Wilmshurst
Journal:  Epilepsia       Date:  2018-09-03       Impact factor: 5.864

4.  Clinical diagnosis of attention-deficit/hyperactivity disorder in survivors of pediatric brain tumors.

Authors:  Emily K Shabason; Cole Brodsky; Julie Baran; Lee Isaac; Jane E Minturn; Jill P Ginsberg; Wendy Hobbie; Michael Fisher; Nathan Blum; Matthew C Hocking
Journal:  J Neurooncol       Date:  2019-04-13       Impact factor: 4.130

5.  Cognitive functioning, behavior, and quality of life after stroke in childhood.

Authors:  Regula Everts; Julia Pavlovic; Franz Kaufmann; Birgit Uhlenberg; Ulrich Seidel; Krassen Nedeltchev; Walter Perrig; Maja Steinlin
Journal:  Child Neuropsychol       Date:  2008-07       Impact factor: 2.500

6.  Attention deficit hyperactivity disorder and neurocognitive correlates after childhood stroke.

Authors:  Jeffrey E Max; Katherine Mathews; Facundo F Manes; Brigitte A M Robertson; Peter T Fox; Jack L Lancaster; Amy E Lansing; Amy Schatz; Nicole Collings
Journal:  J Int Neuropsychol Soc       Date:  2003-09       Impact factor: 2.892

7.  Incidence and predictors of epilepsy after pediatric arterial ischemic stroke.

Authors:  Lori L Billinghurst; Lauren A Beslow; Nicholas S Abend; Michael Uohara; Laura Jastrzab; Daniel J Licht; Rebecca N Ichord
Journal:  Neurology       Date:  2017-01-13       Impact factor: 9.910

8.  The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research.

Authors:  Jonas F Ludvigsson; Petra Otterblad-Olausson; Birgitta U Pettersson; Anders Ekbom
Journal:  Eur J Epidemiol       Date:  2009-06-06       Impact factor: 8.082

9.  Analysis of shared heritability in common disorders of the brain.

Authors:  Verneri Anttila; Brendan Bulik-Sullivan; Hilary K Finucane; Raymond K Walters; Jose Bras; Laramie Duncan; Valentina Escott-Price; Guido J Falcone; Padhraig Gormley; Rainer Malik; Nikolaos A Patsopoulos; Stephan Ripke; Zhi Wei; Dongmei Yu; Phil H Lee; Patrick Turley; Benjamin Grenier-Boley; Vincent Chouraki; Yoichiro Kamatani; Claudine Berr; Luc Letenneur; Didier Hannequin; Philippe Amouyel; Anne Boland; Jean-François Deleuze; Emmanuelle Duron; Badri N Vardarajan; Christiane Reitz; Alison M Goate; Matthew J Huentelman; M Ilyas Kamboh; Eric B Larson; Ekaterina Rogaeva; Peter St George-Hyslop; Hakon Hakonarson; Walter A Kukull; Lindsay A Farrer; Lisa L Barnes; Thomas G Beach; F Yesim Demirci; Elizabeth Head; Christine M Hulette; Gregory A Jicha; John S K Kauwe; Jeffrey A Kaye; James B Leverenz; Allan I Levey; Andrew P Lieberman; Vernon S Pankratz; Wayne W Poon; Joseph F Quinn; Andrew J Saykin; Lon S Schneider; Amanda G Smith; Joshua A Sonnen; Robert A Stern; Vivianna M Van Deerlin; Linda J Van Eldik; Denise Harold; Giancarlo Russo; David C Rubinsztein; Anthony Bayer; Magda Tsolaki; Petra Proitsi; Nick C Fox; Harald Hampel; Michael J Owen; Simon Mead; Peter Passmore; Kevin Morgan; Markus M Nöthen; Martin Rossor; Michelle K Lupton; Per Hoffmann; Johannes Kornhuber; Brian Lawlor; Andrew McQuillin; Ammar Al-Chalabi; Joshua C Bis; Agustin Ruiz; Mercè Boada; Sudha Seshadri; Alexa Beiser; Kenneth Rice; Sven J van der Lee; Philip L De Jager; Daniel H Geschwind; Matthias Riemenschneider; Steffi Riedel-Heller; Jerome I Rotter; Gerhard Ransmayr; Bradley T Hyman; Carlos Cruchaga; Montserrat Alegret; Bendik Winsvold; Priit Palta; Kai-How Farh; Ester Cuenca-Leon; Nicholas Furlotte; Tobias Kurth; Lannie Ligthart; Gisela M Terwindt; Tobias Freilinger; Caroline Ran; Scott D Gordon; Guntram Borck; Hieab H H Adams; Terho Lehtimäki; Juho Wedenoja; Julie E Buring; Markus Schürks; Maria Hrafnsdottir; Jouke-Jan Hottenga; Brenda Penninx; Ville Artto; Mari Kaunisto; Salli Vepsäläinen; Nicholas G Martin; Grant W Montgomery; Mitja I Kurki; Eija Hämäläinen; Hailiang Huang; Jie Huang; Cynthia Sandor; Caleb Webber; Bertram Muller-Myhsok; Stefan Schreiber; Veikko Salomaa; Elizabeth Loehrer; Hartmut Göbel; Alfons Macaya; Patricia Pozo-Rosich; Thomas Hansen; Thomas Werge; Jaakko Kaprio; Andres Metspalu; Christian Kubisch; Michel D Ferrari; Andrea C Belin; Arn M J M van den Maagdenberg; John-Anker Zwart; Dorret Boomsma; Nicholas Eriksson; Jes Olesen; Daniel I Chasman; Dale R Nyholt; Andreja Avbersek; Larry Baum; Samuel Berkovic; Jonathan Bradfield; Russell J Buono; Claudia B Catarino; Patrick Cossette; Peter De Jonghe; Chantal Depondt; Dennis Dlugos; Thomas N Ferraro; Jacqueline French; Helle Hjalgrim; Jennifer Jamnadas-Khoda; Reetta Kälviäinen; Wolfram S Kunz; Holger Lerche; Costin Leu; Dick Lindhout; Warren Lo; Daniel Lowenstein; Mark McCormack; Rikke S Møller; Anne Molloy; Ping-Wing Ng; Karen Oliver; Michael Privitera; Rodney Radtke; Ann-Kathrin Ruppert; Thomas Sander; Steven Schachter; Christoph Schankin; Ingrid Scheffer; Susanne Schoch; Sanjay M Sisodiya; Philip Smith; Michael Sperling; Pasquale Striano; Rainer Surges; G Neil Thomas; Frank Visscher; Christopher D Whelan; Federico Zara; Erin L Heinzen; Anthony Marson; Felicitas Becker; Hans Stroink; Fritz Zimprich; Thomas Gasser; Raphael Gibbs; Peter Heutink; Maria Martinez; Huw R Morris; Manu Sharma; Mina Ryten; Kin Y Mok; Sara Pulit; Steve Bevan; Elizabeth Holliday; John Attia; Thomas Battey; Giorgio Boncoraglio; Vincent Thijs; Wei-Min Chen; Braxton Mitchell; Peter Rothwell; Pankaj Sharma; Cathie Sudlow; Astrid Vicente; Hugh Markus; Christina Kourkoulis; Joana Pera; Miriam Raffeld; Scott Silliman; Vesna Boraska Perica; Laura M Thornton; Laura M Huckins; N William Rayner; Cathryn M Lewis; Monica Gratacos; Filip Rybakowski; Anna Keski-Rahkonen; Anu Raevuori; James I Hudson; Ted Reichborn-Kjennerud; Palmiero Monteleone; Andreas Karwautz; Katrin Mannik; Jessica H Baker; Julie K O'Toole; Sara E Trace; Oliver S P Davis; Sietske G Helder; Stefan Ehrlich; Beate Herpertz-Dahlmann; Unna N Danner; Annemarie A van Elburg; Maurizio Clementi; Monica Forzan; Elisa Docampo; Jolanta Lissowska; Joanna Hauser; Alfonso Tortorella; Mario Maj; Fragiskos Gonidakis; Konstantinos Tziouvas; Hana Papezova; Zeynep Yilmaz; Gudrun Wagner; Sarah Cohen-Woods; Stefan Herms; Antonio Julià; Raquel Rabionet; Danielle M Dick; Samuli Ripatti; Ole A Andreassen; Thomas Espeseth; Astri J Lundervold; Vidar M Steen; Dalila Pinto; Stephen W Scherer; Harald Aschauer; Alexandra Schosser; Lars Alfredsson; Leonid Padyukov; Katherine A Halmi; James Mitchell; Michael Strober; Andrew W Bergen; Walter Kaye; Jin Peng Szatkiewicz; Bru Cormand; Josep Antoni Ramos-Quiroga; Cristina Sánchez-Mora; Marta Ribasés; Miguel Casas; Amaia Hervas; Maria Jesús Arranz; Jan Haavik; Tetyana Zayats; Stefan Johansson; Nigel Williams; Astrid Dempfle; Aribert Rothenberger; Jonna Kuntsi; Robert D Oades; Tobias Banaschewski; Barbara Franke; Jan K Buitelaar; Alejandro Arias Vasquez; Alysa E Doyle; Andreas Reif; Klaus-Peter Lesch; Christine Freitag; Olga Rivero; Haukur Palmason; Marcel Romanos; Kate Langley; Marcella Rietschel; Stephanie H Witt; Soeren Dalsgaard; Anders D Børglum; Irwin Waldman; Beth Wilmot; Nikolas Molly; Claiton H D Bau; Jennifer Crosbie; Russell Schachar; Sandra K Loo; James J McGough; Eugenio H Grevet; Sarah E Medland; Elise Robinson; Lauren A Weiss; Elena Bacchelli; Anthony Bailey; Vanessa Bal; Agatino Battaglia; Catalina Betancur; Patrick Bolton; Rita Cantor; Patrícia Celestino-Soper; Geraldine Dawson; Silvia De Rubeis; Frederico Duque; Andrew Green; Sabine M Klauck; Marion Leboyer; Pat Levitt; Elena Maestrini; Shrikant Mane; Daniel Moreno- De-Luca; Jeremy Parr; Regina Regan; Abraham Reichenberg; Sven Sandin; Jacob Vorstman; Thomas Wassink; Ellen Wijsman; Edwin Cook; Susan Santangelo; Richard Delorme; Bernadette Rogé; Tiago Magalhaes; Dan Arking; Thomas G Schulze; Robert C Thompson; Jana Strohmaier; Keith Matthews; Ingrid Melle; Derek Morris; Douglas Blackwood; Andrew McIntosh; Sarah E Bergen; Martin Schalling; Stéphane Jamain; Anna Maaser; Sascha B Fischer; Céline S Reinbold; Janice M Fullerton; José Guzman-Parra; Fermin Mayoral; Peter R Schofield; Sven Cichon; Thomas W Mühleisen; Franziska Degenhardt; Johannes Schumacher; Michael Bauer; Philip B Mitchell; Elliot S Gershon; John Rice; James B Potash; Peter P Zandi; Nick Craddock; I Nicol Ferrier; Martin Alda; Guy A Rouleau; Gustavo Turecki; Roel Ophoff; Carlos Pato; Adebayo Anjorin; Eli Stahl; Markus Leber; Piotr M Czerski; Cristiana Cruceanu; Ian R Jones; Danielle Posthuma; Till F M Andlauer; Andreas J Forstner; Fabian Streit; Bernhard T Baune; Tracy Air; Grant Sinnamon; Naomi R Wray; Donald J MacIntyre; David Porteous; Georg Homuth; Margarita Rivera; Jakob Grove; Christel M Middeldorp; Ian Hickie; Michele Pergadia; Divya Mehta; Johannes H Smit; Rick Jansen; Eco de Geus; Erin Dunn; Qingqin S Li; Matthias Nauck; Robert A Schoevers; Aartjan Tf Beekman; James A Knowles; Alexander Viktorin; Paul Arnold; Cathy L Barr; Gabriel Bedoya-Berrio; O Joseph Bienvenu; Helena Brentani; Christie Burton; Beatriz Camarena; Carolina Cappi; Danielle Cath; Maria Cavallini; Daniele Cusi; Sabrina Darrow; Damiaan Denys; Eske M Derks; Andrea Dietrich; Thomas Fernandez; Martijn Figee; Nelson Freimer; Gloria Gerber; Marco Grados; Erica Greenberg; Gregory L Hanna; Andreas Hartmann; Matthew E Hirschtritt; Pieter J Hoekstra; Alden Huang; Chaim Huyser; Cornelia Illmann; Michael Jenike; Samuel Kuperman; Bennett Leventhal; Christine Lochner; Gholson J Lyon; Fabio Macciardi; Marcos Madruga-Garrido; Irene A Malaty; Athanasios Maras; Lauren McGrath; Eurípedes C Miguel; Pablo Mir; Gerald Nestadt; Humberto Nicolini; Michael S Okun; Andrew Pakstis; Peristera Paschou; John Piacentini; Christopher Pittenger; Kerstin Plessen; Vasily Ramensky; Eliana M Ramos; Victor Reus; Margaret A Richter; Mark A Riddle; Mary M Robertson; Veit Roessner; Maria Rosário; Jack F Samuels; Paul Sandor; Dan J Stein; Fotis Tsetsos; Filip Van Nieuwerburgh; Sarah Weatherall; Jens R Wendland; Tomasz Wolanczyk; Yulia Worbe; Gwyneth Zai; Fernando S Goes; Nicole McLaughlin; Paul S Nestadt; Hans-Jorgen Grabe; Christel Depienne; Anuar Konkashbaev; Nuria Lanzagorta; Ana Valencia-Duarte; Elvira Bramon; Nancy Buccola; Wiepke Cahn; Murray Cairns; Siow A Chong; David Cohen; Benedicto Crespo-Facorro; James Crowley; Michael Davidson; Lynn DeLisi; Timothy Dinan; Gary Donohoe; Elodie Drapeau; Jubao Duan; Lieuwe Haan; David Hougaard; Sena Karachanak-Yankova; Andrey Khrunin; Janis Klovins; Vaidutis Kučinskas; Jimmy Lee Chee Keong; Svetlana Limborska; Carmel Loughland; Jouko Lönnqvist; Brion Maher; Manuel Mattheisen; Colm McDonald; Kieran C Murphy; Igor Nenadic; Jim van Os; Christos Pantelis; Michele Pato; Tracey Petryshen; Digby Quested; Panos Roussos; Alan R Sanders; Ulrich Schall; Sibylle G Schwab; Kang Sim; Hon-Cheong So; Elisabeth Stögmann; Mythily Subramaniam; Draga Toncheva; John Waddington; James Walters; Mark Weiser; Wei Cheng; Robert Cloninger; David Curtis; Pablo V Gejman; Frans Henskens; Morten Mattingsdal; Sang-Yun Oh; Rodney Scott; Bradley Webb; Gerome Breen; Claire Churchhouse; Cynthia M Bulik; Mark Daly; Martin Dichgans; Stephen V Faraone; Rita Guerreiro; Peter Holmans; Kenneth S Kendler; Bobby Koeleman; Carol A Mathews; Alkes Price; Jeremiah Scharf; Pamela Sklar; Julie Williams; Nicholas W Wood; Chris Cotsapas; Aarno Palotie; Jordan W Smoller; Patrick Sullivan; Jonathan Rosand; Aiden Corvin; Benjamin M Neale; Jonathan M Schott; Richard Anney; Josephine Elia; Maria Grigoroiu-Serbanescu; Howard J Edenberg; Robin Murray
Journal:  Science       Date:  2018-06-22       Impact factor: 47.728

Review 10.  Why the Diagnosis of Attention Deficit Hyperactivity Disorder Matters.

Authors:  Alaa M Hamed; Aaron J Kauer; Hanna E Stevens
Journal:  Front Psychiatry       Date:  2015-11-26       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.